Mission Wealth Management LP Sells 1,896 Shares of Amgen Inc. (NASDAQ:AMGN)

Mission Wealth Management LP trimmed its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,463 shares of the medical research company's stock after selling 1,896 shares during the period. Mission Wealth Management LP's holdings in Amgen were worth $2,727,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the 3rd quarter valued at approximately $25,000. Centricity Wealth Management LLC bought a new position in Amgen in the fourth quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the third quarter valued at approximately $29,000. Heck Capital Advisors LLC bought a new stake in Amgen during the fourth quarter worth $36,000. Finally, PrairieView Partners LLC boosted its holdings in shares of Amgen by 118.3% in the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company's stock valued at $46,000 after purchasing an additional 97 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last 90 days. Corporate insiders own 0.69% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Leerink Partners lowered their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Piper Sandler lifted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $314.09.

Amgen Trading Up 0.5 %

Amgen stock traded up $1.41 during mid-day trading on Tuesday, hitting $312.19. 3,819,193 shares of the stock were exchanged, compared to its average volume of 2,546,395. The stock has a market capitalization of $167.71 billion, a price-to-earnings ratio of 41.35, a PEG ratio of 2.63 and a beta of 0.56. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm's fifty day simple moving average is $281.80 and its two-hundred day simple moving average is $299.73.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.05%. Amgen's payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.